Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» solid tumors
solid tumors
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment
Fierce Biotech
Novartis
Legend Biotech
CAR-T
T-Charge
solid tumors
Flag link:
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Flag link:
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Fierce Biotech
Roche
diabetic retinopathy
solid tumors
bispecific antibodies
Flag link:
Adlai Nortye IPO gives old Novartis cancer drug new life
Adlai Nortye IPO gives old Novartis cancer drug new life
BioPharma Dive
Adlai Nortye
IPOs
Novartis
AN2025
head and neck cancer
solid tumors
Flag link:
1ST Biotherapeutics and Merck to assess cancer combination treatment
1ST Biotherapeutics and Merck to assess cancer combination treatment
Clinical Trials Arena
Merck
1st Biotherapeutics
Keytruda
solid tumors
clinical trials
Flag link:
FDA grants clearance to Harbour’s IND for solid tumors therapy trial
FDA grants clearance to Harbour’s IND for solid tumors therapy trial
Clinical Trials Arena
Harbour BioMed
clinical trials
HBM9033
solid tumors
Flag link:
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
Roche’s Divarasib Scores Phase I Win in KRAS-Mutated Solid Tumors
BioSpace
Roche
Genentech
divarasib
KRAS inhibitors
solid tumors
clinical trials
Flag link:
Moderna, CARsgen Join Forces Combining mRNA Cancer Vaccine with CAR T
Moderna, CARsgen Join Forces Combining mRNA Cancer Vaccine with CAR T
BioSpace
Moderna Therapeutics
CARsgen
MRNA
cancer
cancer vaccine
vaccines
solid tumors
CAR-T
Flag link:
Moderna reveals Claudin18.2 ambitions via cancer vaccine, solid tumor CAR-T combo plans
Moderna reveals Claudin18.2 ambitions via cancer vaccine, solid tumor CAR-T combo plans
Fierce Biotech
Moderna Therapeutics
Claudin18.2
MRNA
vaccines
CAR-T
cancer vaccine
solid tumors
Flag link:
Bio-Thera reports positive data from solid tumors therapy trial
Bio-Thera reports positive data from solid tumors therapy trial
Clinical Trials Arena
Bio-Thera Solutions
solid tumors
clinical trials
BAT8006
Flag link:
FDA clears Qualigen’s IND for trial of solid tumour therapy
FDA clears Qualigen’s IND for trial of solid tumour therapy
Clinical Trials Arena
Qualigen Therapeutics
clinical trials
solid tumors
QN-302
Flag link:
Enhertu offers survival benefits in Phase II solid tumour trial
Enhertu offers survival benefits in Phase II solid tumour trial
Clinical Trials Arena
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
solid tumors
Flag link:
Roche Decides Not to Exercise Solid Tumor Option with SQZ
Roche Decides Not to Exercise Solid Tumor Option with SQZ
BioSpace
Roche
solid tumors
SQZ Biotech
Flag link:
Rain Oncology to cut 65% of staff after milademetan Phase 3 trial failure
Rain Oncology to cut 65% of staff after milademetan Phase 3 trial failure
Medical Marketing and Media
Rain Oncology
layoffs
clinical trials
milademetan
oncology
solid tumors
Flag link:
Xilio reports preliminary data from Phase I solid tumors therapy trial
Xilio reports preliminary data from Phase I solid tumors therapy trial
Clinical Trials Arena
Xilio Therapeutics
clinical trials
solid tumors
XTX101
Flag link:
UCB partners with Ariceum for treatment of immune-related diseases and cancer
UCB partners with Ariceum for treatment of immune-related diseases and cancer
Biopharma Reporter
UCB Pharma
Ariceum
R&D
radiopharmaceuticals
solid tumors
Flag link:
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas
BioSpace
Novartis
earnings
solid tumors
hematology
immunology
Neuroscience
cardiovascular disease
Flag link:
Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear
Roche, seeing MAGE magic wane, makes pair of solid tumor bispecifics disappear
Fierce Biotech
Roche
earnings
solid tumors
MAGE-A4
Flag link:
FDA clears Sensei’s IND to start Phase I/II therapy trial of SNS-101
FDA clears Sensei’s IND to start Phase I/II therapy trial of SNS-101
Clinical Trials Arena
Sensei Biotherapeutics
SNS-101
clinical trials
solid tumors
Flag link:
BMS signs ADC development deal with Munich-based biotech worth more than $1B
BMS signs ADC development deal with Munich-based biotech worth more than $1B
Medical Marketing and Media
Bristol Myers Squibb
Tubulius
cancer
solid tumors
antibody-drug conjugate
Flag link:
Pages
1
2
3
4
5
6
7
8
9
next ›
last »